6th Microbiome Movement - Drug Development Summit

Memo

The most comprehensive forum for microbiome drug developers, the Microbiome Movement - Drug Development Summit returns for its sixth iteration! The advancing scientific and clinical landscape, mixed with the high quality audience that we bring together has made this the must attendconference for those translating microbiome science into clinically successful therapeutics. There is increased excitement around this years' discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic, key functions are beginning to be understood and the number of clinical candidates are increasing. However, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges, and is once again the center of the 6th Microbiome Movement - Drug Development Summit. The Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease, and develop a new generation of microbiome-targetedtherapeutics with predictable modes of action and consistent clinical outcomes. From understanding microbiome functionality, leveraging lessons from clinical development and scaling manufacturing processes, through to leveraging microbiome biomarkers for patient stratification and diagnostics, our discussion will cover the latest scientific findings andindustry updates from the end-to-end development of microbiome therapeutics. There is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients, and we hope that you can join this years' discussion to help towards the development of effective treatments across a range of indications, and push microbiome products closer to commercialization. Running digitally June 29 - July 1, 2021. Group discounts and early booking rates are available. Please visit the website for full pricing information. URLs:Tickets: https://go.evvnt.com/740368-1?pid=5569 Brochure: https://go.evvnt.com/740368-3?pid=5569  Date and Time: On Tuesday June 29, 2021 at 9:00 am (ends Thursday July 01, 2021 at 5:00 pm) Prices:Conference + Pre-Conference Focus Day (Drug Developer: Pharma and Biotech): USD 2597.00,Conference Pass (Drug Developer: Pharma and Biotech): USD 1999.00,Conference + Pre-Conference Focus Day (Academic and Not-For Profit): USD 1597.00,Conference Pass (Academic and Not-For Profit): USD 1199.00,Conference + Pre-Conference Focus Day (Solution Provider): USD 3197.00,Conference Pass (Solution Provider): USD 2499.00 Speakers: Gokul Swaminathan, Associate Principal Scientist, Investigational Biology, Merck Exploratory Science, Ken Blount, CSO, Rebiotix, Matthew Henn, Executive VP and CSO, Seres Therapeutics, Stephanie Culler, Co-Founder and CEO, Persephone Biosciences, Fyza Shaikh, Instructor, John Hopkins Medical Center, Mark Smith, CEO, Finch Therapeutics, Nancy Caralla, Founding President and Executive Director, C.diff Foundation, Paul Carlson, Principal Investigator, FDA, Christophe Carite, Director, CMC and Development, 4D Pharma, Mark Bamforth, President and CEO, Arranta Bio, Morten Isaksen, CEO, Bio-Me, Jonathan Solomon, CEO, BiomX, Yvonne Nyavor, Principal Scientist, Microbiome, Boston Analytical, Dan Knights, CEO, CoreBiome, Manoj Dadlani, CEO, CosmosID, Emily Drabant Conley, CEO, Federation Bio, Andrea Nuzzo, Computational Biologist, GSK, Kate Jefferey, Assistant Professor of Medicine, Harvard Medical School, Tuval Ben-Yehezkel, CEO, Loop Genomics, Xue Liang, Microbiome Scientist, Merck Exploratory Science Center, Blake Wise, CEO, Novome Biotechnologies, Jeanette Mucha, CEO, SciBac, Chris Ford, Senior Director, Computational Microbiome Scientist, Seres Therapeutics, Denise Kelly, Investment Advisor, Seventure Partners, Ricardo Valladares, CSO, Siolta Therapeutics, Julie Schwedock, Associate Director, Microbial Development, Takeda, Bernat Olle, CEO, Vedanta Biosciences